Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:G02CX02
|
| gptkbp:CASNumber |
167933-07-5
|
| gptkbp:contraindication |
alcohol use
liver impairment |
| gptkbp:developedBy |
gptkb:Boehringer_Ingelheim
gptkb:Sprout_Pharmaceuticals |
| gptkbp:eliminationHalfLife |
11 hours
|
| gptkbp:hasMolecularFormula |
C20H21F3N4O
|
| https://www.w3.org/2000/01/rdf-schema#label |
flibanserin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Addyi
|
| gptkbp:mechanismOfAction |
5-HT2A receptor antagonist
5-HT1A receptor agonist dopamine receptor modulator |
| gptkbp:pregnancyCategory |
N (Not classified)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness fatigue somnolence |
| gptkbp:synonym |
gptkb:Addyi
BIMT-17 |
| gptkbp:usedFor |
treatment of hypoactive sexual desire disorder
|
| gptkbp:bfsParent |
gptkb:Addyi
|
| gptkbp:bfsLayer |
7
|